← Back

Ion Beam Applications S.A.

15.20+38.0%1Y · EUR

Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatment, serious illnesses, and industrial applications. It operates in Belgium, the United States, China, Germany, and India through four segments: Clinical Proton Therapy, Clinical Dosimetry, IBA Technologies, and IBA Corporate. The company develops technologies such as ConformalFLASH, DynamicARC, Proteus ONE, and Proteus PLUS, along with dosimetry solutions including QUASAR phantoms. It also offers radio pharma solutions, integrated industrial solutions, and services, and has a research partnership with SCK CEN. Incorporated in 1986, it is headquartered in Louvain-la-Neuve, Belgium.

Price · split & dividend adjusted
News & notes moving 0GZK.LSE
Belgium
0GZK.LSE

IBA Discloses Transparency Notification as Vallcara Limited Crosses 7.5% Voting Rights Threshold

IBA, the Belgian proton therapy company, announced it has issued a transparency notification after Vallcara Limited, a wholly owned subsidiary of Vallgesa Limited, crossed the 7.5% voting rights threshold. The notification, received on September 28, 2026, states that Vallcara Limited now holds 3,090,766 voting rights, representing 7.50% of the denominator of 41,197,996, following an acquisition of shares. Vallgesa Limited itself holds no voting rights, and the full chain of controlled undertakings shows Vallcara Limited is 100% held by Vallgesa Limited, which is not a controlled entity. The disclosure was made under Article 14, paragraph 1 of the Belgian Transparency Law of May 2, 2007 on the disclosure of major holdings. IBA, based in Louvain-la-Neuve, Belgium, employs approximately 2,300 people worldwide and is listed on Euronext under the ticker IBAB.
0GZK.LSE · Capital · Neutral IBA disclosed a transparency notification after Vallcara crossed the 7.5% voting rights threshold, a shareholder-structure event with no clear directional impact
Vallcara Limited · Capital · Neutral Vallcara Limited acquired shares to cross the 7.5% voting rights threshold in IBA, a stake-building event of unclear direction
Vallgesa Limited · Capital · Neutral Vallgesa Limited is the parent of Vallcara, which crossed the 7.5% threshold in IBA; Vallgesa itself holds no voting rights
Read original ↗
Bloomberg·5dRead more →
Italy
Biotech & Genomic Medicine▲

IBA Signs Contract for First Proton Therapy Center in Central and Southern Italy

IBA has signed a contract with the Istituti Fisioterapici Ospitalieri & Istituto Nazionale Tumori Regina Elena, known as IFO, to provide a turnkey proton therapy solution in Rome, Italy, the first gantry-based proton therapy system available in central and southern Italy. Following a public tender, IBA and its partners Cecchini SRL and Gowen SRL, construction companies and RTI members, were selected by IFO to deliver a turnkey compact gantry-based ProteusONE system at the Istituti Fisioterapici Ospitalieri center in Rome, for both pediatric and adult patients. The contract covers the latest-generation ProteusONE system, design, build, installation, a comprehensive training and education program, and a one-year operation and maintenance agreement, with IFO expecting to start treating patients in 2030. The typical end user price of a ProteusONE system with a multiyear maintenance contract ranges between 35 million euros and 45 million euros. Henri de Romree, Deputy Chief Executive Officer of IBA, said the project will make gantry-based proton therapy available to patients in central and southern Italy for the first time, while Giuseppe Navanteri, Chief Clinical Engineering and Technology officer of IFO, called it an important step forward in expanding access to advanced cancer care in the region.
About megatrends
Biotech & Genomic Medicine › Oncology Therapeutics Technology
0GZK.LSE · Demand · Positive IBA signed a contract with IFO to supply a turnkey ProteusONE proton therapy system in Rome, a concrete order for its product.
Cecchini SRL · Demand · Positive Cecchini SRL is named as an RTI member/partner selected to help deliver the turnkey proton therapy project.
Gowen SRL · Demand · Positive Gowen SRL is named as an RTI member/partner selected to help deliver the turnkey proton therapy project.
Read original ↗
Yahoo Finance·7dRead more →
Biotech & Genomic Medicine▲

IBA va installer le premier centre de protonthérapie du Brésil à Rio de Janeiro

IBA a signé un contrat avec la Fundação Severino Sombra pour l'acquisition d'un système Proteus®ONE, en vue de créer le premier centre de protonthérapie du Brésil à Barra da Tijuca, Rio de Janeiro. Ce centre sera principalement dédié aux cancers pédiatriques et développé en collaboration avec l'Institut national du cancer. Le contrat inclut la fourniture du système de dernière génération, tandis qu'un accord pluriannuel d'exploitation et de maintenance sera négocié ultérieurement. Les premiers patients devraient être traités au premier semestre 2030. Le prix usuel d'une solution Proteus®ONE avec maintenance pluriannuelle se situe entre 35 et 45 millions d'euros.
About megatrends
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Demand
0GZK.LSE · Demand · Positive IBA signed a contract to supply a ProteusONE system for Brazil's first proton therapy center, with typical deal value €35-45M.
Read original ↗
GlobeNewswire·103dRead more →